Approval · Notice of Compliance 25916 · 2021
TRURAPI: Notice of Compliance 25916
Issued May 20, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25916
- Date
- May 20, 2021
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to product monograph
- Canadian reference product
- NOVORAPID
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRURAPI | Not yet assigned | — |
Medicinal ingredients
- INSULIN ASPART 10.5 MG per CART
- INSULIN ASPART 100 MG per PEN